Search

Your search keyword '"Tomasso, Annamaria"' showing total 49 results
Start Over Author "Tomasso, Annamaria"
49 results on '"Tomasso, Annamaria"'

1. Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience.

Author

Innocenti, Idanna, Mosca, Antonio, Tomasso, Annamaria, Galitzia, Andrea, Scarfò, Lydia, Morelli, Francesca, Galli, Eugenio, Martini, Francesca, Sangiorgi, Eugenio, Laureana, Roberta, Benintende, Giulia, Mattiello, Veronica, Chiriu, Sabrina, Del Principe, Maria I., Zamprogna, Giulia, Gentile, Massimo, Martino, Enrica A., Cappello, Emilia, Montalbano, Maria C., and Farina, Giuliana

Published
2024
Full Text
View/download PDF

3. What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study

Author

D'Arena, G., Vitale, C., Pietrantuono, G., Villani, O., Mansueto, G., D'Auria, Francesca, Statuto, T., D'Agostino, Stefano, Sabetta, R., Tarasco, Angelina, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Valvano, L., Tomasso, Annamaria, Cafaro, L., Lamorte, D., Laurenti, Luca, D'Auria F., D'Agostino S., Tarasco A., Innocenti I., Autore F., Fresa A., Tomasso A., Laurenti L. (ORCID:0000-0002-8327-1396), D'Arena, G., Vitale, C., Pietrantuono, G., Villani, O., Mansueto, G., D'Auria, Francesca, Statuto, T., D'Agostino, Stefano, Sabetta, R., Tarasco, Angelina, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Valvano, L., Tomasso, Annamaria, Cafaro, L., Lamorte, D., Laurenti, Luca, D'Auria F., D'Agostino S., Tarasco A., Innocenti I., Autore F., Fresa A., Tomasso A., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Atypical chronic lymphocytic leukemia (CLL) is still defined according to morphological criteria. However, deviance from the typical surface immunological profile suggests an atypical immunological-based CLL. A large cohort of patients with CLL was retrospectively evaluated aiming at assessing morphological (FAB criteria), immunophenotypical (two or more discordances from the typical profile), and clinical–biological features of atypical CLL. Compared to typical cases, morphologically atypical CLL showed a greater percentage of unmutated IgVH and CD38 positivity, and a higher expression of CD20. Immunophenotypically atypical CLL was characterized by more advanced clinical stages, higher expression of CD20, higher rate of FMC7, CD79b and CD49d positivity, and by an intermediate–high expression of membrane surface immunoglobulin, compared to typical cases. When patients were categorized based on immunophenotypic and morphologic concordance or discordance, no difference emerged. Finally, morphological features better discriminated patients’ prognosis in terms of time-to-first treatment, while concordant atypical cases showed overall a worse prognosis. Discordant cases by immunophenotype and/or morphology did not identify specific prognostic groups. Whether—in the era of molecular markers used as prognostic indicators—it does make sense to focus on morphology and immunophenotype features in CLL is still matter of debate needing further research.

Published
2024

4. What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study

Author

D’Arena, Giovanni, primary, Vitale, Candida, additional, Pietrantuono, Giuseppe, additional, Villani, Oreste, additional, Mansueto, Giovanna, additional, D’Auria, Fiorella, additional, Statuto, Teodora, additional, D’Agostino, Simona, additional, Sabetta, Rosalaura, additional, Tarasco, Angela, additional, Innocenti, Idanna, additional, Autore, Francesco, additional, Fresa, Alberto, additional, Valvano, Luciana, additional, Tomasso, Annamaria, additional, Cafaro, Lorenzo, additional, Lamorte, Daniela, additional, and Laurenti, Luca, additional

Published
2024
Full Text
View/download PDF

5. Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience

Author

Innocenti, Idanna, primary, Fresa, Alberto, additional, Tomasso, Annamaria, additional, Tarnani, Michela, additional, De Padua, Laura, additional, Benintende, Giulia, additional, Pasquale, Raffaella, additional, Galli, Eugenio, additional, Morelli, Francesca, additional, Giannarelli, Diana, additional, Autore, Francesco, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

6. P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.

Author

Innocenti, Idanna, primary, Tomasso, Annamaria, additional, Mosca, Antonio, additional, Benintende, Giulia, additional, Colalelli, Michela, additional, Galli, Eugenio, additional, Chiusolo, Patrizia, additional, Metafuni, Elisabetta, additional, Giammarco, Sabrina, additional, Sorà, Federica, additional, Assunta Limongiello, Maria, additional, Fresa, Alberto, additional, Stirparo, Luca, additional, Lamberti, Fabio, additional, Autore, Francesco, additional, Bacigalupo, Andrea, additional, Hohaus, Stefan, additional, De Stefano, Valerio, additional, Sica, Simona, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

7. PB1933: TREATMENT SEQUENCING AND OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS: A THIRTY-YEAR SINGLE-CENTER EXPERIENCE.

Author

Fresa, Alberto, primary, Autore, Francesco, additional, Innocenti, Idanna, additional, Tomasso, Annamaria, additional, Iadevaia, Francesco, additional, Stirparo, Luca, additional, Mosca, Antonio, additional, Benintende, Giulia, additional, Galli, Eugenio, additional, Giannarelli, Diana, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

8. PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

Author

Innocenti, Idanna, primary, Mosca, Antonio, additional, Tomasso, Annamaria, additional, Galitzia, Andrea, additional, Scarfò, Lydia, additional, Galli, Eugenio, additional, Laureana, Roberta, additional, Benintende, Giulia, additional, Mattiello, Veronica, additional, Morelli, Francesca, additional, Chiriu, Sabrina, additional, Del Principe, Maria Ilaria, additional, Zamprogna, Giulia, additional, Gentile, Massimo, additional, Fabbri, Nicole, additional, Autore, Francesco, additional, Sportoletti, Paolo, additional, Fresa, Alberto, additional, Catania, Gioacchino, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Sanna, Alessandro, additional, Varettoni, Marzia, additional, Ghia, Paolo, additional, Murru, Roberta, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

9. Richter transformation in Chronic Lymphocytic Leukemia

Author

Innocenti, Idanna, Benintende, G., Tomasso, Annamaria, Fresa, Alberto, Autore, Francesco, Larocca, Luigi Maria, Laurenti, Luca, Innocenti I., Tomasso A., Fresa A., Autore F., Larocca L. M. (ORCID:0000-0003-1739-4758), Laurenti L. (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Benintende, G., Tomasso, Annamaria, Fresa, Alberto, Autore, Francesco, Larocca, Luigi Maria, Laurenti, Luca, Innocenti I., Tomasso A., Fresa A., Autore F., Larocca L. M. (ORCID:0000-0003-1739-4758), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Chronic lymphocytic leukemia can evolve to an aggressive lymphoma—in most of the cases diffuse large B cells lymphoma, rarely Hodgkin lymphoma—and this complication is defined Richter syndrome (RS). Immunogenotypic features that characterize RS include unmutated IgHV status with high prevalence of IgHV4-39/D6-13/J5 sequence; deletion of chromosome 17p or 11q; activation of oncogenes as NOTCH1 and c-MYC; inactivation of onco-suppressors as TP53 and CDKN2A; high expression of CD38 in lymph-nodes. The prognosis of this condition is very poor: patients experience a rapid clinical deterioration with frequent therapeutic failure since the current options include suboptimal strategies as standard chemo-immunotherapy followed by hematopoietic stem cells transplantation or enrollment in clinical trials which investigate the efficacy of target drugs. Understanding the biology of such a heterogeneous condition is crucial to personalize the treatment and improve patient's survival.

Published
2023

10. Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience

Author

Innocenti, Idanna, Fresa, Alberto, Tomasso, Annamaria, Tarnani, Michela, De Padua, L., Benintende, G., Pasquale, R., Galli, Eugenio, Morelli, F., Giannarelli, Diana, Autore, Francesco, Laurenti, Luca, Innocenti I., Fresa A., Tomasso A., Tarnani M., Galli E. (ORCID:0000-0002-2839-916X), Giannarelli D., Autore F., Laurenti L. (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Fresa, Alberto, Tomasso, Annamaria, Tarnani, Michela, De Padua, L., Benintende, G., Pasquale, R., Galli, Eugenio, Morelli, F., Giannarelli, Diana, Autore, Francesco, Laurenti, Luca, Innocenti I., Fresa A., Tomasso A., Tarnani M., Galli E. (ORCID:0000-0002-2839-916X), Giannarelli D., Autore F., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Background: This monocentric retrospective study describes the treatment patterns and outcomes of chronic lymphocytic leukemia (CLL) patients. Methods: Adult CLL patients treated between 1992 and 2022 were included. The time to next treatment (TTNT) was defined as the time from the treatment’s start to the start of a subsequent therapy or death. The time to next treatment failure or death (TTNTF) was defined as the time from treatment discontinuation to the discontinuation of a subsequent therapy or death. Results: Of 637 registered patients, 318 (49.9%) received treatment. We evaluated 157 cBTKi-exposed, 34 BCL2i-exposed cBTKi-naïve, and 26 double-exposed patients. The five-year TTNT values in the cBTKi-exposed patients were 80% (median NR), 40% (median 40 months), and 21% (median 24 months) months in the first line (1L), second line (2L), and beyond the second line (>2L), respectively (p < 0.0001). The five-year TTNT values in the BCL2i-exposed patients were 83% (median NR), 72% (median NR), 12% (median 28 months) in the 1L, 2L, and >2L, respectively (p = 0.185). The median TTNTF was 9 months (range 1–87) after cBTKi and 17 months (range 8–49) after both a cBTKi and BCL2i. Conclusions: This study suggests that, in CLL patients, the earlier we used targeted therapies, the better was the outcome obtained. Nonetheless, the poor outcomes in the advanced lines of therapy highlight the need for more effective treatments.

Published
2023

11. Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study

Author

Benintende, Giulia, Innocenti, Idanna, Fresa, Alberto, Autore, Francesco, Tomasso, Annamaria, Piciocchi, Alfonso, Vuono, Florenzia, Stirparo, Luca, Mosca, Antonio, Bacigalupo, Andrea, Gattei, Valter, Efremov, Dimitar, Sangiorgi, Eugenio, Laurenti, Luca, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sangiorgi, Eugenio (ORCID:0000-0001-9079-9175), Laurenti, Luca (ORCID:0000-0002-8327-1396), Benintende, Giulia, Innocenti, Idanna, Fresa, Alberto, Autore, Francesco, Tomasso, Annamaria, Piciocchi, Alfonso, Vuono, Florenzia, Stirparo, Luca, Mosca, Antonio, Bacigalupo, Andrea, Gattei, Valter, Efremov, Dimitar, Sangiorgi, Eugenio, Laurenti, Luca, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sangiorgi, Eugenio (ORCID:0000-0001-9079-9175), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2023

12. What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.

Author

D'Arena, Giovanni, Vitale, Candida, Pietrantuono, Giuseppe, Villani, Oreste, Mansueto, Giovanna, D'Auria, Fiorella, Statuto, Teodora, D'Agostino, Simona, Sabetta, Rosalaura, Tarasco, Angela, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Valvano, Luciana, Tomasso, Annamaria, Cafaro, Lorenzo, Lamorte, Daniela, and Laurenti, Luca

Subjects
CHRONIC lymphocytic leukemia, FLOW cytometry, RETROSPECTIVE studies, ACQUISITION of data, CANCER patients, GENE expression, SYMPTOMS, MEDICAL records, IMMUNOPHENOTYPING, TUMOR markers, PHENOTYPES
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) may be atypical in terms of the cell morphology picture, but also with regard to the surface immunophenotypic profile. Aiming at assessing the impact of morphology and immunophenotype in defining the atypical characteristics of CLL in terms of clinical–biological features and prognosis, a retrospective analysis of a large cohort of CLL patients was performed. We found that morphology better predicts the prognosis of atypical CLL compared to immunophenotypic analysis. Also, discordant cases in terms of immunophenotype and morphology did not identify specific prognostic groups. Overall, the question that still needs to be answered is: does it make sense to focus on morphology and immunophenotypic features in CLL in the era of molecular markers used as prognostic indicators? Atypical chronic lymphocytic leukemia (CLL) is still defined according to morphological criteria. However, deviance from the typical surface immunological profile suggests an atypical immunological-based CLL. A large cohort of patients with CLL was retrospectively evaluated aiming at assessing morphological (FAB criteria), immunophenotypical (two or more discordances from the typical profile), and clinical–biological features of atypical CLL. Compared to typical cases, morphologically atypical CLL showed a greater percentage of unmutated IgVH and CD38 positivity, and a higher expression of CD20. Immunophenotypically atypical CLL was characterized by more advanced clinical stages, higher expression of CD20, higher rate of FMC7, CD79b and CD49d positivity, and by an intermediate–high expression of membrane surface immunoglobulin, compared to typical cases. When patients were categorized based on immunophenotypic and morphologic concordance or discordance, no difference emerged. Finally, morphological features better discriminated patients' prognosis in terms of time-to-first treatment, while concordant atypical cases showed overall a worse prognosis. Discordant cases by immunophenotype and/or morphology did not identify specific prognostic groups. Whether—in the era of molecular markers used as prognostic indicators—it does make sense to focus on morphology and immunophenotype features in CLL is still matter of debate needing further research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study

Author

Benintende, Giulia, primary, Innocenti, Idanna, additional, Fresa, Alberto, additional, Autore, Francesco, additional, Tomasso, Annamaria, additional, Piciocchi, Alfonso, additional, Vuono, Florenzia, additional, Stirparo, Luca, additional, Mosca, Antonio, additional, Bacigalupo, Andrea, additional, Gattei, Valter, additional, Efremov, Dimitar, additional, Sangiorgi, Eugenio, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

16. Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres

Author

Innocenti, Idanna, primary, Murru, Roberta, additional, Benintende, Giulia, additional, Galitzia, Andrea, additional, Mosca, Antonio, additional, Barabino, Luca, additional, Stirparo, Luca, additional, Tomasso, Annamaria, additional, Fresa, Alberto, additional, Autore, Francesco, additional, Caocci, Giovanni, additional, La Nasa, Giorgio, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

17. VEGF and IL-6 As Markers of Severity and Response to Treatment in Waldenstrom Macroglobulinemia and IgM-Monoclonal Gammopathy of Undetermined Significance: A Monocentric Experience

Author

Tomasso, Annamaria, primary, Innocenti, Idanna, additional, Benintende, Giulia, additional, Autore, Francesco, additional, Fresa, Alberto, additional, Vuono, Florenzia, additional, Stirparo, Luca, additional, Mosca, Antonio, additional, Giannotta, Claudia, additional, Efremov, Dimitar G, additional, Luigetti, Marco, additional, Baroni, Silvia, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

18. Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Author

Benintende, Giulia, primary, Innocenti, Idanna, additional, Fresa, Alberto, additional, Autore, Francesco, additional, Tomasso, Annamaria, additional, Vuono, Florenzia, additional, Stirparo, Luca, additional, Mosca, Antonio, additional, Efremov, Dimitar G, additional, Bacigalupo, Andrea, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

19. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia

Author

Moia, Riccardo, primary, Dondolin, Riccardo, additional, De Propris, Maria Stefania, additional, Talotta, Donatella, additional, Mouhssine, Samir, additional, Perutelli, Francesca, additional, Reda, Gianluigi, additional, Mattiello, Veronica, additional, Rigolin, Gian Matteo, additional, Motta, Marina, additional, Olivieri, Jacopo, additional, Fanin, Renato, additional, Perbellini, Omar, additional, Ferrarini, Isacco, additional, Mauro, Francesca Romana, additional, Del Giudice, Ilaria, additional, Laurenti, Luca, additional, Tomasso, Annamaria, additional, Gentile, Massimo, additional, Frustaci, Anna Maria, additional, Tedeschi, Alessandra, additional, Gozzetti, Alessandro, additional, Stelitano, Caterina, additional, Visco, Carlo, additional, Moreno, Carol, additional, Forconi, Francesco, additional, Marasca, Roberto, additional, Coscia, Marta, additional, Rossi, Davide, additional, Foà, Robin, additional, and Gaidano, Gianluca, additional

Published
2022
Full Text
View/download PDF

20. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia.

Author

Moia, Riccardo, Dondolin, Riccardo, De Propris, Maria Stefania, Talotta, Donatella, Mouhssine, Samir, Perutelli, Francesca, Reda, Gianluigi, Mattiello, Veronica, Rigolin, Gian Matteo, Motta, Marina, Olivieri, Jacopo, Fanin, Renato, Perbellini, Omar, Ferrarini, Isacco, Mauro, Francesca Romana, Del Giudice, Ilaria, Laurenti, Luca, Tomasso, Annamaria, Gentile, Massimo, and Frustaci, Anna Maria

Subjects
CHRONIC lymphocytic leukemia, NUCLEOTIDE sequencing, FLUORESCENCE in situ hybridization, LOW-income countries, CHRONIC leukemia
Abstract

The I EGR2 i gene, coding for a transcription factor that also mediates the I TP53 i dependent apoptotic pathway, was found to be mutated in 3 patients (8.6%), and further stratifies the outcome of low-risk patients. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. [Extracted from the article]

Published
2023
Full Text
View/download PDF

21. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Author

Fresa, Alberto, Autore, Francesco, Piciocchi, Alfonso, Catania, Gioacchino, Visentin, Andrea, Tomasso, Annamaria, Moretti, Marina, Vitale, Candida, Chiarenza, Annalisa, Morelli, Francesca, Sportoletti, Paolo, Marasca, Roberto, Sapienza, Giuseppe, Cuccaro, Annarosa, Murru, Roberta, Sanna, Alessandro, Patti, Caterina, Angeletti, Ilaria, Coscia, Marta, Trentin, Livio, Pietrasanta, Daniela, Innocenti, Idanna, and Laurenti, Luca

Published
2022
Full Text
View/download PDF

22. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Author

Innocenti, Idanna, Reda, Gianluigi, Visentin, Andrea, Coscia, Marta, Motta, Marina, Murru, Roberta, Moia, Riccardo, Gentile, Massimo, Pennese, Elsa, Quaglia, Francesca Maria, Albano, Francesco, Cassin, Ramona, Deodato, Marina, Ielo, Claudia, Frustaci, Anna Maria, Piciocchi, Alfonso, Rughini, Arianna, Arena, Valentina, Di Sevo, Daniela, Tomasso, Annamaria, Autore, Francesco, Del Poeta, Giovanni, Scarfò, Lydia, Mauro, Francesca Romana, Tedeschi, Alessandra, Trentin, Livio, Pompili, Maurizio, Foà, Robin, Ghia, Paolo, Cuneo, Antonio, Laurenti, Luca, Pompili, Maurizio (ORCID:0000-0001-6699-7980), Laurenti, Luca (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Reda, Gianluigi, Visentin, Andrea, Coscia, Marta, Motta, Marina, Murru, Roberta, Moia, Riccardo, Gentile, Massimo, Pennese, Elsa, Quaglia, Francesca Maria, Albano, Francesco, Cassin, Ramona, Deodato, Marina, Ielo, Claudia, Frustaci, Anna Maria, Piciocchi, Alfonso, Rughini, Arianna, Arena, Valentina, Di Sevo, Daniela, Tomasso, Annamaria, Autore, Francesco, Del Poeta, Giovanni, Scarfò, Lydia, Mauro, Francesca Romana, Tedeschi, Alessandra, Trentin, Livio, Pompili, Maurizio, Foà, Robin, Ghia, Paolo, Cuneo, Antonio, Laurenti, Luca, Pompili, Maurizio (ORCID:0000-0001-6699-7980), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2022

23. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Author

Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., Foa R., Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., and Foa R.

Abstract

NA

Published
2022

24. Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study

Author

Benintende, Giulia, Innocenti, Idanna, Fresa, Alberto, Autore, Francesco, Tomasso, Annamaria, Piciocchi, Alfonso, Vuono, Florenzia, Stirparo, Luca, Mosca, Antonio, Bacigalupo, Andrea, Gattei, Valter, Efremov, Dimitar, Sangiorgi, Eugenio, Laurenti, Luca, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sangiorgi, Eugenio (ORCID:0000-0001-9079-9175), Laurenti, Luca (ORCID:0000-0002-8327-1396), Benintende, Giulia, Innocenti, Idanna, Fresa, Alberto, Autore, Francesco, Tomasso, Annamaria, Piciocchi, Alfonso, Vuono, Florenzia, Stirparo, Luca, Mosca, Antonio, Bacigalupo, Andrea, Gattei, Valter, Efremov, Dimitar, Sangiorgi, Eugenio, Laurenti, Luca, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sangiorgi, Eugenio (ORCID:0000-0001-9079-9175), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

n/a

Published
2022

25. VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response

Author

Tomasso, Annamaria, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Benintende, G., Vuono, Florenzia, Baroni, Silvia, Giannotta, C., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Tomasso A., Innocenti I., Autore F., Fresa A., Vuono F., Baroni S. (ORCID:0000-0002-3410-2617), Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso, Annamaria, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Benintende, G., Vuono, Florenzia, Baroni, Silvia, Giannotta, C., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Tomasso A., Innocenti I., Autore F., Fresa A., Vuono F., Baroni S. (ORCID:0000-0002-3410-2617), Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2022

26. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics

Author

Innocenti, Idanna, Tomasso, Annamaria, Benintende, G., Autore, Francesco, Fresa, Alberto, Vuono, Florenzia, Stirparo, Luca, Galli, Eugenio, D'Arena, G., Sora', Federica, Efremov, D., Laurenti, Luca, Innocenti I., Tomasso A., Autore F., Fresa A., Vuono F., Stirparo L., Galli E. (ORCID:0000-0002-2839-916X), Sora F. (ORCID:0000-0002-9607-5298), Laurenti L. (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Tomasso, Annamaria, Benintende, G., Autore, Francesco, Fresa, Alberto, Vuono, Florenzia, Stirparo, Luca, Galli, Eugenio, D'Arena, G., Sora', Federica, Efremov, D., Laurenti, Luca, Innocenti I., Tomasso A., Autore F., Fresa A., Vuono F., Stirparo L., Galli E. (ORCID:0000-0002-2839-916X), Sora F. (ORCID:0000-0002-9607-5298), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid-19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase-free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid-19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid-19 era, because of the self-administration at home which results in improvement in the QoL and reduced treatment expenditures.

Published
2022

27. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Author

Innocenti, Idanna, primary, Reda, Gianluigi, additional, Visentin, Andrea, additional, Coscia, Marta, additional, Motta, Marina, additional, Murru, Roberta, additional, Moia, Riccardo, additional, Gentile, Massimo, additional, Pennese, Elsa, additional, Quaglia, Francesca Maria, additional, Albano, Francesco, additional, Cassin, Ramona, additional, Deodato, Marina, additional, Ielo, Claudia, additional, Frustaci, Anna Maria, additional, Piciocchi, Alfonso, additional, Rughini, Arianna, additional, Arena, Valentina, additional, Di Sevo, Daniela, additional, Tomasso, Annamaria, additional, Autore, Francesco, additional, Del Poeta, Giovanni, additional, Scarfò, Lydia, additional, Mauro, Francesca Romana, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Pompili, Maurizio, additional, Foà, Robin, additional, Ghia, Paolo, additional, Cuneo, Antonio, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

28. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics

Author

Innocenti, Idanna, primary, Tomasso, Annamaria, additional, Benintende, Giulia, additional, Autore, Francesco, additional, Fresa, Alberto, additional, Vuono, Florenzia, additional, Stirparo, Luca, additional, Galli, Eugenio, additional, D’Arena, Giovanni, additional, Sorà, Federica, additional, Efremov, Dimitar, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

29. VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.

Author

Laurenti, Luca, primary, Innocenti, Idanna, additional, Benintende, Giulia, additional, Tomasso, Annamaria, additional, Autore, Francesco, additional, Fresa, Alberto, additional, Vuono, Florenzia, additional, Baroni, Silvia, additional, Giannotta, Claudia, additional, Chiusolo, Patrizia, additional, Sorà, Federica, additional, and Sica, Simona, additional

Published
2022
Full Text
View/download PDF

31. CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia

Author

D’Arena, Giovanni, primary, Vitale, Candida, additional, Coscia, Marta, additional, Lamorte, Daniela, additional, Pietrantuono, Giuseppe, additional, Perutelli, Francesca, additional, D’Auria, Fiorella, additional, Statuto, Teodora, additional, Valvano, Luciana, additional, Tomasso, Annamaria, additional, Griggio, Valentina, additional, Jones, Rebecca, additional, Mansueto, Giovanna, additional, Villani, Oreste, additional, D’Agostino, Simona, additional, Viglioglia, Vito, additional, De Feo, Vincenzo, additional, Calapai, Fabrizio, additional, Mannucci, Carmen, additional, Sgambato, Alessandro, additional, Efremov, Dimitar G., additional, and Laurenti, Luca, additional

Published
2021
Full Text
View/download PDF

32. Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Author

Innocenti, Idanna, Mosca, Antonio, Tomasso, Annamaria, Galitzia, Andrea, Scarfo, Lydia, Galli, Eugenio, Laureana, Roberta, Benintende, Giulia, Mattiello, Veronica, Morelli, Francesca, Chiriu, Sabrina, Del Principe, Maria Ilaria, Frustaci, Annamaria, Zamprogna, Giulia, Gentile, Massimo, Fabbri, Nicole, Autore, Francesco, Montalbano, Maria Chiara, Farina, Giuliana, Innao, Vanessa, Patti, Caterina, Sportoletti, Paolo, Fresa, Alberto, Catania, Gioacchino, Coscia, Marta, Tedeschi, Alessandra, Sanna, Alessandro, Visentin, Andrea, Trentin, Livio, Varettoni, Marzia, Ghia, Paolo, Murru, Roberta, and Laurenti, Luca

Published
2023
Full Text
View/download PDF

33. Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Author

Innocenti, Idanna, Tomasso, Annamaria, Mosca, Antonio, Colalelli, Michela, Benintende, Giulia, Galli, Eugenio, Chiusolo, Patrizia, Metafuni, Elisabetta, Giammarco, Sabrina, Sorà, Federica, Limongiello, Maria Assunta, Fresa, Alberto, Stirparo, Luca, Lamberti, Fabio, Autore, Francesco, Bacigalupo, Andrea, Hohaus, Stefan, De Stefano, Valerio, Sica, Simona, and Laurenti, Luca

Published
2023
Full Text
View/download PDF

34. Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review

Author

Fresa, Alberto, Autore, Francesco, Galli, Eugenio, Tomasso, Annamaria, Stirparo, Luca, Innocenti, Idanna, Laurenti, Luca, Fresa A., Autore F., Galli E. (ORCID:0000-0002-2839-916X), Tomasso A., Stirparo L., Innocenti I., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa, Alberto, Autore, Francesco, Galli, Eugenio, Tomasso, Annamaria, Stirparo, Luca, Innocenti, Idanna, Laurenti, Luca, Fresa A., Autore F., Galli E. (ORCID:0000-0002-2839-916X), Tomasso A., Stirparo L., Innocenti I., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Chronic lymphocytic leukemia (CLL) incidence increases with age reaching 37.9/100,000 in patients over 85 years. Although there is no standardized geriatric tool specifically validated for CLL, a correct framing of the fitness status is of critical importance to individualize treatment strategies. Based on the evidence available to date, frontline chemoimmunotherapy has an increasingly narrowing application, being eligible for candidacy only in elderly fit patients without or with minimal geriatric syndromes. On the other hand, treatment with BCR inhibitors, monotherapy, or in combination with anti-CD20 antibodies (e.g., obinutuzumab), must be preferred both for frontline and relapsed CLL not only in unfit patients, but also in fit patients with unmutated IGHV or harboring del(17p) and/or TP53 mutations/deletions. Second-generation inhibitors (e.g., acalabrutinib, zanubrutinib, pirtobrutinib) are novel compounds that, due to their better safety profile and different specificity, will help physicians overcome some of the safety issues and treatment resistances. In the era of targeted therapies, treatment decisions in elderly and/or unfit patients with CLL must be a balance between efficacy and safety, carefully evaluating comorbidities and geriatric syndromes to ensure the best approach to improve both quality of life and life expectancy.

Published
2021

35. Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia

Author

Fresa, Alberto, Autore, Francesco, Innocenti, Idanna, Piciocchi, A., Tomasso, Annamaria, Morelli, F., Sora', Federica, Sica, Simona, De Stefano, Valerio, Laurenti, Luca, Fresa A., Autore F., Innocenti I., Tomasso A., Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), Laurenti L. (ORCID:0000-0002-8327-1396), Fresa, Alberto, Autore, Francesco, Innocenti, Idanna, Piciocchi, A., Tomasso, Annamaria, Morelli, F., Sora', Federica, Sica, Simona, De Stefano, Valerio, Laurenti, Luca, Fresa A., Autore F., Innocenti I., Tomasso A., Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Infusion-related reactions are among the worst complications of obinutuzumab (G) administration and occur predominantly during the first infusion. We reported another adverse event related to the first G infusion, a subclinical coagulopathy. We retrospectively analyzed a cohort of 13 pts with chronic lymphocytic leukemia treated with a frontline G-chlorambucil regimen. Six pts developed non-overt disseminated intravascular coagulopathy (DIC) (46%) after the first administration of G. The coagulopathy was subclinical and self-limited in all pts, not requiring any intervention apart from the suspension of anticoagulant therapy in one pt. We observed a drop in the platelet count, an elevation of D-dimer levels, and an elongation of activated partial thromboplastin time. We found a significant difference in the platelet count between the pts with DIC and those withouts; in fact, all the six pts with non-overt DIC had a platelet count greater than 100 × 109/L, while in the other group only one (p = 0.019). A trend towards a lower lymphocyte count and a higher CD20 expression was found in the pts with DIC. No other correlation between the DIC complication and the clinical or laboratory characteristics of the patients was found. The pathogenesis of the G-related non-overt DIC could be related to the consumption of the platelets after the lysis of lymphocytes, probably triggered by the damage associated molecular patterns. Despite its limitations, this study describes a new adverse event and identifies a specific subgroup of patients whose clinical management at the time of the infusion of G may need to be refined.

Published
2021

36. Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia

Author

Fresa, Alberto, primary, Autore, Francesco, additional, Innocenti, Idanna, additional, Piciocchi, Alfonso, additional, Tomasso, Annamaria, additional, Morelli, Francesca, additional, Sorà, Federica, additional, Sica, Simona, additional, De Stefano, Valerio, additional, and Laurenti, Luca, additional

Published
2021
Full Text
View/download PDF

38. Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia

Author

Corbingi, Andrea, primary, Innocenti, Idanna, additional, Tomasso, Annamaria, additional, Pasquale, Raffaella, additional, Visentin, Andrea, additional, Varettoni, Marzia, additional, Flospergher, Elena, additional, Autore, Francesco, additional, Morelli, Francesca, additional, Trentin, Livio, additional, Reda, Gianluigi, additional, Efremov, Dimitar G., additional, and Laurenti, Luca, additional

Published
2020
Full Text
View/download PDF

39. Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia

Author

Corbingi, A., Innocenti, Idanna, Tomasso, Annamaria, Pasquale, R., Visentin, A., Varettoni, M., Flospergher, E., Autore, Francesco, Morelli, F., Trentin, L., Reda, G., Efremov, D. G., Laurenti, Luca, Innocenti I., Tomasso A., Autore F., Laurenti L. (ORCID:0000-0002-8327-1396), Corbingi, A., Innocenti, Idanna, Tomasso, Annamaria, Pasquale, R., Visentin, A., Varettoni, M., Flospergher, E., Autore, Francesco, Morelli, F., Trentin, L., Reda, G., Efremov, D. G., Laurenti, Luca, Innocenti I., Tomasso A., Autore F., and Laurenti L. (ORCID:0000-0002-8327-1396)

Published
2020

40. Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience

Author

Laurenti, Luca, primary, Corbingi, Andrea, additional, Innocenti, Idanna, additional, Tomasso, Annamaria, additional, Pasquale, Raffaella, additional, Visentin, Andrea, additional, Varettoni, Marzia, additional, Autore, Francesco, additional, Morelli, Francesca, additional, Trentin, Livio, additional, and Reda, Gianluigi, additional

Published
2019
Full Text
View/download PDF

43. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax

Author

Innocenti, Idanna, Morelli, Francesca, Autore, Francesco, Tomasso, Annamaria, Corbingi, Andrea, Bellesi, Silvia, Za, Tommaso, De Stefano, Valerio, Laurenti, Luca, De Stefano, Valerio (ORCID:0000-0002-5178-5827), Laurenti, Luca (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Morelli, Francesca, Autore, Francesco, Tomasso, Annamaria, Corbingi, Andrea, Bellesi, Silvia, Za, Tommaso, De Stefano, Valerio, Laurenti, Luca, De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

na

Published
2019

44. CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia.

Author

D'Arena, Giovanni, Vitale, Candida, Coscia, Marta, Lamorte, Daniela, Pietrantuono, Giuseppe, Perutelli, Francesca, D'Auria, Fiorella, Statuto, Teodora, Valvano, Luciana, Tomasso, Annamaria, Griggio, Valentina, Jones, Rebecca, Mansueto, Giovanna, Villani, Oreste, D'Agostino, Simona, Viglioglia, Vito, De Feo, Vincenzo, Calapai, Fabrizio, Mannucci, Carmen, and Sgambato, Alessandro

Subjects
CHRONIC lymphocytic leukemia, ACQUISITION of data methodology, MULTIVARIATE analysis, CASE-control method, RETROSPECTIVE studies, MEMBRANE glycoproteins, MEDICAL records, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics, SURVIVAL analysis (Biometry), TUMOR markers
Abstract

Simple Summary: This study aimed at investigating the prognostic significance of the soluble form of CD200 antigen evaluated at diagnosis in patients with chronic lymphocytic leukemia (CLL). In a large cohort of patients, we found that more aggressive features and a worse prognosis are correlated with higher baseline serum levels of CD200. These data support the relevant role of CD200 not only as a diagnostic tool but also as a prognostic indicator and a potential therapeutic target in CLL. Membrane-bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200's prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and in 78 age- and sex-matched healthy subjects using a specific human CD200 (OX-2 membrane glycoprotein) ELISA kit. A significantly higher concentration of sCD200 was found in CLL patients compared to controls. In our cohort, sCD200 was significantly higher in patients who were older than 66 years, with Binet stage C, unmutated IgVH and unfavorable (del11q or del17p) FISH. Time-to-first treatment and overall survival were significantly shorter in patients with higher sCD200 concentration, using as a cut-off 1281 pg/mL, the median value for sCD200 concentration in the whole CLL cohort. However, the prognostic impact of sCD200 was not confirmed in multivariate analysis. Baseline sCD200 values appeared to have an impact on the response to chemotherapy or chemo-immunotherapy, but not to targeted agents. Collectively, our data show that sCD200 serum levels correlate with more aggressive clinical and biological features and are able to predict a worse prognosis. This work supports the relevant role of CD200 not only as a diagnostic tool but also as a prognostic indicator and a potential therapeutic target in CLL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Author

Idanna Innocenti, Gianluigi Reda, Andrea Visentin, Marta Coscia, Marina Motta, Roberta Murru, Riccardo Moia, Massimo Gentile, Elsa Pennese, Francesca Maria Quaglia, Francesco Albano, Ramona Cassin, Marina Deodato, Claudia Ielo, Anna Maria Frustaci, Alfonso Piciocchi, Arianna Rughini, Valentina Arena, Daniela Di Sevo, Annamaria Tomasso, Francesco Autore, Giovanni Del Poeta, Lydia Scarfò, Francesca Romana Mauro, Alessandra Tedeschi, Livio Trentin, Maurizio Pompili, Robin Foà, Paolo Ghia, Antonio Cuneo, Luca Laurenti, Innocenti, Idanna, Reda, Gianluigi, Visentin, Andrea, Coscia, Marta, Motta, Marina, Murru, Roberta, Moia, Riccardo, Gentile, Massimo, Pennese, Elsa, Quaglia, Francesca Maria, Albano, Francesco, Cassin, Ramona, Deodato, Marina, Ielo, Claudia, Frustaci, Anna Maria, Piciocchi, Alfonso, Rughini, Arianna, Arena, Valentina, Di Sevo, Daniela, Tomasso, Annamaria, Autore, Francesco, Del Poeta, Giovanni, Scarfò, Lydia, Mauro, Francesca Romana, Tedeschi, Alessandra, Trentin, Livio, Pompili, Maurizio, Foà, Robin, Ghia, Paolo, Cuneo, Antonio, and Laurenti, Luca

Subjects
Hepatitis B virus, Adenine, occult HBV infection, HBV reactivation, Hematology, Antiviral Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Settore MED/15 - MALATTIE DEL SANGUE, Hepatitis B, Chronic, Piperidines, ibrutinib, Humans, Virus Activation, Chronic lymphocytic leukemia, Retrospective Studies
Abstract

Not available.

Published
2022

47. Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Author

Innocenti I, Tomasso A, Giannarelli D, Scarfò L, Murru R, Visentin A, Frustaci AM, Morelli F, Vitale C, Mosca A, Sanna A, Farina G, Laureana R, Gentile M, Galitzia A, Pasquale R, Autore F, Olivieri J, Romeo A, Deodato M, Stirparo L, Corbingi A, Innao V, Perutelli F, Martini F, Sportoletti P, Fresa A, Del Principe MI, Tedeschi A, Coscia M, Ghia P, and Laurenti L

Published
2025
Full Text
View/download PDF

48. Richter transformation in Chronic Lymphocytic Leukemia.

Author

Innocenti I, Benintende G, Tomasso A, Fresa A, Autore F, Larocca LM, and Laurenti L

Subjects
Humans, Prognosis, Cell Transformation, Neoplastic genetics, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Hodgkin Disease pathology
Abstract

Chronic lymphocytic leukemia can evolve to an aggressive lymphoma-in most of the cases diffuse large B cells lymphoma, rarely Hodgkin lymphoma-and this complication is defined Richter syndrome (RS). Immunogenotypic features that characterize RS include unmutated IgHV status with high prevalence of IgHV4-39/D6-13/J5 sequence; deletion of chromosome 17p or 11q; activation of oncogenes as NOTCH1 and c-MYC; inactivation of onco-suppressors as TP53 and CDKN2A; high expression of CD38 in lymph-nodes. The prognosis of this condition is very poor: patients experience a rapid clinical deterioration with frequent therapeutic failure since the current options include suboptimal strategies as standard chemo-immunotherapy followed by hematopoietic stem cells transplantation or enrollment in clinical trials which investigate the efficacy of target drugs. Understanding the biology of such a heterogeneous condition is crucial to personalize the treatment and improve patient's survival., (© 2022 John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results